Brief: Seres Therapeutics Reports Ser-155 Phase 1B Cohort 1 Results Showing Successful Drug Bacteria Engraftment And Substantial Reduction In Pathogen Domination In The Gastrointestinal Microbiome

Seres Therapeutics

09/05/2023 13:06

May 9 (Reuters) - Seres Therapeutics Inc  MCRB.O :
    * SERES THERAPEUTICS REPORTS SER-155 PHASE 1B COHORT 1
RESULTS
SHOWING SUCCESSFUL DRUG BACTERIA ENGRAFTMENT AND SUBSTANTIAL
REDUCTION IN PATHOGEN DOMINATION IN THE GASTROINTESTINAL
MICROBIOME
    * SERES THERAPEUTICS REPORTS SER-155 PHASE 1B COHORT 1
RESULTS
SHOWING SUCCESSFUL DRUG BACTERIA ENGRAFTMENT AND SUBSTANTIAL
REDUCTION IN PATHOGEN DOMINATION IN THE GASTROINTESTINAL
MICROBIOME
    * SERES THERAPEUTICS INC - TOLERABILITY PROFILE OBSERVED
SUPPORTS
CONTINUED DEVELOPMENT IN COHORT 2, WITH NO TREATMENT ATTRIBUTED
SERIOUS ADVERSE EVENTS
    * SERES THERAPEUTICS INC - REDUCTION IN INCIDENCES OF
MICROBIOME
PATHOGEN DOMINATION PROVIDES SUPPORT FOR INTENDED SER-155
CLINICAL ACTIVITY
    * SERES THERAPEUTICS INC - SER-155 PHASE 1B
PLACEBO-CONTROLLED
COHORT 2 DATA READOUT ANTICIPATED IN MID-2024

Source text for Eikon:  ID:nBw32smZWa 
Further company coverage:  MCRB.O 

 ((Reuters.Briefs@thomsonreuters.com;))